After finishing at $0.71 in the prior trading day, DermTech Inc (NASDAQ: DMTK) closed at $0.70, down -0.99%. In other words, the price has decreased by -$0.0070 from its previous closing price. On the day, 162971 shares were traded.
Ratios:
Our goal is to gain a better understanding of DMTK by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.52 and its Current Ratio is at 4.59. In the meantime, Its Debt-to-Equity ratio is 0.95 whereas as Long-Term Debt/Eq ratio is at 0.90.
On June 14, 2022, BTIG Research reiterated its Buy rating and also upped its target price recommendation from $38 to $19.
On January 07, 2022, Stephens started tracking the stock assigning a Overweight rating and target price of $26.Stephens initiated its Overweight rating on January 07, 2022, with a $26 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 11 ’23 when Sun Kevin M sold 447 shares for $1.45 per share. The transaction valued at 648 led to the insider holds 277,499 shares of the business.
Ibarra Claudia sold 331 shares of DMTK for $480 on Dec 11 ’23. The Chief Operating Officer now owns 193,547 shares after completing the transaction at $1.45 per share. On Dec 08 ’23, another insider, Ibarra Claudia, who serves as the Chief Operating Officer of the company, sold 2,607 shares for $1.41 each. As a result, the insider received 3,676 and left with 193,878 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DMTK now has a Market Capitalization of 24.06M and an Enterprise Value of 22.59M. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.59 while its Price-to-Book (P/B) ratio in mrq is 0.42. Its current Enterprise Value per Revenue stands at 1.48 whereas that against EBITDA is -0.23.
Stock Price History:
Over the past 52 weeks, DMTK has reached a high of $4.67, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is 1.0626, while the 200-Day Moving Average is calculated to be 1.7724.
Shares Statistics:
The stock has traded on average 363.80K shares per day over the past 3-months and 220.62k shares per day over the last 10 days, according to various share statistics. A total of 34.52M shares are outstanding, with a floating share count of 30.61M. Insiders hold about 11.60% of the company’s shares, while institutions hold 16.47% stake in the company. Shares short for DMTK as of Mar 15, 2024 were 3.14M with a Short Ratio of 8.64, compared to 3.32M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 9.08% and a Short% of Float of 9.37%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.57 for the current quarter, with a high estimate of -$0.54 and a low estimate of -$0.59, while EPS last year was -$1.02. The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.42 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$1.62 and -$2.26 for the fiscal current year, implying an average EPS of -$1.99. EPS for the following year is -$1.62, with 5 analysts recommending between -$0.84 and -$2.23.
Revenue Estimates
6 analysts predict $3.96M in revenue for the current quarter. It ranges from a high estimate of $4.2M to a low estimate of $3.7M. As of the current estimate, DermTech Inc’s year-ago sales were $3.48M, an estimated increase of 13.90% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $4.26M, an increase of 15.40% over than the figure of $13.90% in the same quarter last year. There is a high estimate of $4.6M for the next quarter, whereas the lowest estimate is $3.9M.
A total of 6 analysts have provided revenue estimates for DMTK’s current fiscal year. The highest revenue estimate was $19.8M, while the lowest revenue estimate was $16.3M, resulting in an average revenue estimate of $17.68M. In the same quarter a year ago, actual revenue was $15.3M, up 15.60% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $21.7M in the next fiscal year. The high estimate is $24.2M and the low estimate is $19.89M. The average revenue growth estimate for next year is up 22.70% from the average revenue estimate for this year.
